Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 2/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 2/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.32 |
| ▸ | FABP7 | O15540 | 1/20 | 0.32 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.31 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.31 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.31 |
| ▸ | VCP | P55072 | 2/20 | 0.31 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2921894 | 0.98 | PDE9A (0.36) | PDE9AHRH1PDE4APDE4BPDE4C | |
| SCHEMBL677024 | 0.98 | PDE9A (0.36) | PDE9AHRH1PDE4APDE4BPDE4C | |
| SCHEMBL233125 | 0.98 | PDE9A (0.36) | PDE9AHRH1PDE4APDE4BPDE4C | |
| SCHEMBL232553 | 0.96 | HRH1 (0.33) | PDE9AHRH1PDE4APDE4BPDE4C | |
| SCHEMBL709427 | 0.92 | HRH1 (0.35) | HRH1 | |
| SCHEMBL677022 | 0.90 | HRH1 (0.32) | HRH1 | |
| SCHEMBL6530733 | 0.90 | PDE9A (0.35) | PDE9APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4352771 | 0.89 | HRH1 (0.30) | HRH1 | |
| SCHEMBL677299 | 0.86 | PDE9A (0.30) | PDE9A | |
| SCHEMBL4361390 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106458937-A | Diaminotriazine derivatives as herbicides | 巴斯夫欧洲公司 | 2017-02-22 | — | — | CN | claimed |
| EP-2356103-B1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | TAKEDA GMBH (DE) | 2015-08-26 | — | — | EP | claimed |
| CN-102369194-B | Pyrazolone derivatives and their use as PD4 inhibitors | NYCOMED GMBH | 2014-08-27 | — | — | CN | claimed |
| US-8609848-B2 | Pyrazolone-derivatives and their use as PDE-4 inhibitors | TAKEDA GMBH (DE) | 2013-12-17 | — | — | US | claimed |
| CN-102369194-A | Novel pyrazolone derivatives and their use as PD4 inhibitors | NYCOMED GMBH | 2012-03-07 | — | — | CN | claimed |
| US-20110218201-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE-4 INHIBITORS | NYCOMED GMBH (DE) | 2011-09-08 | — | — | US | claimed |
| EP-2356103-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PD4 INHIBITORS | Nycomed GmbH (DE) | 2011-08-17 | — | — | EP | claimed |
| WO-2010055083-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PD4 INHIBITORS | NYCOMED GMBH (DE) | 2010-05-20 | — | — | WO | claimed |
| US-20090312344-A1 | ARYLPIPERAZINE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-12-17 | — | — | US | claimed |
| US-20070219216-A1 | 1-Alkylpiperazinyl-Pyrrolidin-2,5-Dione Derivatives as Adrenergic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2007-09-20 | — | — | US | claimed |
| EP-1682145-A1 | 1-ALKYLPIPERAZINYL-PYRROLIDIN-2,5-DIONE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2006-07-26 | — | — | EP | claimed |
| EP-1668007-A1 | DIOXOLANE DERIVATIVES AS CELL ADHESION INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2006-06-14 | — | — | EP | claimed |
| WO-2006051399-A1 | PIPERAZINE DERIVATIVES USEFUL AS ADRENERGIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-05-18 | — | — | WO | claimed |
| WO-2005118537-A2 | ARYLPIPERAZINE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2005-12-15 | — | — | WO | claimed |
| WO-2005037282-A1 | 1-ALKYLPIPERAZINYL-PYRROLIDIN-2,5-DIONE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2005-04-28 | — | — | WO | claimed |
| WO-2005026163-A1 | DIOXOLANE DERIVATIVES AS CELL ADHESION INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2005-03-24 | — | — | WO | claimed |
| EP-1399445-A2 | SUBSTITUTED PYRROLOQUINOLINES AND PYRIDOQUINOLINES AS SEROTONIN AGONISTS AND ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-03-24 | — | — | EP | claimed |
| US-6436961-B1 | SUBSTANCE P RECEPTOR ANTAGONIST; 2-PHENYL-3-BENZYLAMINOPIPERIDINES | PFIZER INC | 2002-08-20 | — | — | US | claimed |
| WO-2002059124-A2 | SUBSTITUTED PYRROLOQUINOLINES AND PYRIDOQUINOLINES AS SEROTONIN AGONISTS AND ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-01 | — | — | WO | claimed |
| US-3971804-A | ACARICIDES, FUNGICIDES, INSECTICIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-07-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219216-A1 | 1-Alkylpiperazinyl-Pyrrolidin-2,5-Dione Derivatives as Adrenergic Receptor Antagonists | ADRA1D, ADRA1A, ADRB1 | PDE9A 539/4885HRH1 142/4885PDE4A 138/4885 |
| US-20090312344-A1 | ARYLPIPERAZINE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS | ADRA1D, ADRB1, ADRA1A | PDE9A 617/4885HRH1 68/4885PDE4A 168/4885 |
| US-20110218201-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE-4 INHIBITORS | PDE4A, PDE3B, PDE3A | PDE9A 12/4885HRH1 3322/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.